# West Gene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/west-gene

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.westgenepharma.com
- Total disclosed funding: $42M
- Latest round: Series A (Jun 15, 2023)
- Investors on record: 5

## About

Founded in 2021, and based in Chengdu, China, West Gene is a Biomedical Technology Company that engages in the R&D, manufacturing, and sales of mRNA drugs. Xiangrong Song, the co-founder of the company, was once engaged in mRNA drug related research at Harvard Medical School. The company's team members involved multiple disciplines, including biology, immunology, computer aided drug design, and others. Also, the company has over 20 patents. Besides, WestGene has achieved breakthroughs on R&D of mRNA drugs, including the design of mRNA sequence core elements, targeting delivery systems and scale-up production. In June 2023, West Gene raised CNY 300 million in series A funding from new investors Beijing Konruns Pharmaceutical Co., Ltd., Geuniom Group, Huaxin Assets, returning investors Tigermed, and Yingke Private Equity, an individual investor, and other unspecified investors. 

The company's product pipelines include preventive vaccine platform, antitumor immunotherapy vaccine platform, gene editing treatment platform, protein replacement therapy platform, and adjuvant platform. The preventive vaccine platform includes COVID-19 virus vaccine, malaria vaccine, dengue vaccine, and respiratory syncytial virus vaccine. Antitumor immunotherapy vaccine include EBV positive tumour vaccine, liver cancer vaccine, stomach cancer vaccine, and ovarian cancer vaccine, and others. And the gene editing treatment platform has four pipelines, including anti-cancer antibodies, COVID-19 therapy antibodies, obesity drugs, and anti-ageing drugs.

## Funding rounds

- Series A, Jun 15, 2023, $42M — Yingke Private Equity, Beijing Konruns Pharmaceutical Co., Ltd., Tigermed, Geuniom Group, Huaxin Assets
- Angel, Dec 17, 2021 — Yingke Private Equity, Tigermed

## Investors

- Yingke Private Equity (https://capitalatlas.ai/funds/yingke-private-equity) — Angel, Series A
- Tigermed (https://capitalatlas.ai/funds/tigermed) — Angel, Series A
- Beijing Konruns Pharmaceutical Co., Ltd. — Series A
- Geuniom Group — Series A
- Huaxin Assets — Series A